Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | RUNX1 | Q01196 | 2/20 | 0.40 |
| ▸ | ALPL | P05186 | 2/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14534817 | 0.88 | GPR3 (0.46) | GPR3PPARDFFAR4FFAR1 | |
| SCHEMBL14499403 | 0.86 | MCHR1 (0.46) | CA12CA9PPARDFFAR4FFAR1 | |
| SCHEMBL12180463 | 0.85 | GPR3 (0.44) | GPR3CA12CA1CA2CA7 | |
| SCHEMBL16952355 | 0.85 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12422184 | 0.84 | CA12 (0.61) | GPR3CA12CA1CA2CA7 | |
| SCHEMBL13431467 | 0.82 | CA12 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3563216 | 0.81 | GPR3 (0.41) | GPR3PPARDFFAR4FFAR1 | |
| SCHEMBL5158453 | 0.81 | ALDH1A1 (0.46) | GPR3CA12CA1CA2CA7 | |
| SCHEMBL16953616 | 0.80 | PPARD (0.47) | GPR3PPARDFFAR4FFAR1 | |
| SCHEMBL16955239 | 0.80 | PPARD (0.41) | GPR3PPARDFFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150374-A1 | INDUCERS OF KLF2 AND METHODS OF USE THEREOF | RIPARIAN PHARMACEUTICALS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2019217957-A1 | QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-11-14 | — | — | WO | disclosed |
| EP-2968316-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3461809-A1 | TETRACYCLINE COMPOUNDS | Tetraphase Pharmaceuticals, Inc. (US) | 2019-04-03 | — | — | EP | disclosed |
| US-20170247311-A1 | CYCLOBUTANE CONTAINING CARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170002014-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2017-01-05 | — | — | US | disclosed |
| EP-2733534-B1 | COMPOSITION FOR FORMING FINE PATTERN AND METHOD FOR FORMING FINED PATTERN USING SAME | MERCK PATENT GMBH (DE) | 2016-09-14 | — | — | EP | disclosed |
| US-9416132-B2 | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9315494-B2 | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-19 | — | — | US | disclosed |
| US-9298094-B2 | Composition for forming fine pattern and method for forming fined pattern using same | MERCK PATENT GMBH (DE) | 2016-03-29 | — | — | US | disclosed |
| EP-1562589-B1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080312223-A1 | Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080312223-A1 | Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2005002552-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K5 | GPR3 1852/4885CA12 4228/4885CA1 2384/4885 |
| US-20080312223-A1 | Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases | CDK1, CDK8, CDK2 | GPR3 1780/4885CA12 1631/4885CA1 1002/4885 |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | CDK1, AURKA, CDK2 | GPR3 4155/4885CA12 4180/4885CA1 4014/4885 |
| US-20170247311-A1 | CYCLOBUTANE CONTAINING CARBOXYLIC ACID GPR120 MODULATORS | GPR68, GPR88, GPR55 | GPR3 9/4885CA12 1732/4885CA1 2539/4885 |
| US-20170002014-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | GPR3 1922/4885CA12 3387/4885CA1 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.